Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization by Jamileh Hashemi et al.
Hashemi et al. BMC Cancer 2013, 13:505
http://www.biomedcentral.com/1471-2407/13/505RESEARCH ARTICLE Open AccessCopy number alterations in small intestinal
neuroendocrine tumors determined by array
comparative genomic hybridization
Jamileh Hashemi1*, Omid Fotouhi1, Luqman Sulaiman1, Magnus Kjellman2,3, Anders Höög1, Jan Zedenius1,3
and Catharina Larsson1Abstract
Background: Small intestinal neuroendocrine tumors (SI-NETs) are typically slow-growing tumors that have
metastasized already at the time of diagnosis. The purpose of the present study was to further refine and define
regions of recurrent copy number (CN) alterations (CNA) in SI-NETs.
Methods: Genome-wide CNAs was determined by applying array CGH (a-CGH) on SI-NETs including 18 primary
tumors and 12 metastases. Quantitative PCR analysis (qPCR) was used to confirm CNAs detected by a-CGH as well
as to detect CNAs in an extended panel of SI-NETs. Unsupervised hierarchical clustering was used to detect tumor
groups with similar patterns of chromosomal alterations based on recurrent regions of CN loss or gain. The log rank
test was used to calculate overall survival. Mann–Whitney U test or Fisher’s exact test were used to evaluate
associations between tumor groups and recurrent CNAs or clinical parameters.
Results: The most frequent abnormality was loss of chromosome 18 observed in 70% of the cases. CN losses were
also frequently found of chromosomes 11 (23%), 16 (20%), and 9 (20%), with regions of recurrent CN loss identified
in 11q23.1-qter, 16q12.2-qter, 9pter-p13.2 and 9p13.1-11.2. Gains were most frequently detected in chromosomes
14 (43%), 20 (37%), 4 (27%), and 5 (23%) with recurrent regions of CN gain located to 14q11.2, 14q32.2-32.31,
20pter-p11.21, 20q11.1-11.21, 20q12-qter, 4 and 5. qPCR analysis confirmed most CNAs detected by a-CGH as well
as revealed CNAs in an extended panel of SI-NETs. Unsupervised hierarchical clustering of recurrent regions of CNAs
revealed two separate tumor groups and 5 chromosomal clusters. Loss of chromosomes 18, 16 and 11 and gain of
chromosome 20 were found in both tumor groups. Tumor group II was enriched for alterations in chromosome
cluster-d, including gain of chromosomes 4, 5, 7, 14 and gain of 20 in chromosome cluster-b. Gain in 20pter-p11.21
was associated with short survival. Statistically significant differences were observed between primary tumors and
metastases for loss of 16q and gain of 7.
Conclusion: Our results revealed recurrent CNAs in several candidate regions with a potential role in SI-NET
development. Distinct genetic alterations and pathways are involved in tumorigenesis of SI-NETs.
Keywords: Small intestine, Neuroendocrine tumor, Carcinoid, Array CGH, Chromosome 18* Correspondence: Jamileh.Hashemi@ki.se
1Department of Oncology-Pathology, Karolinska Institutet, Cancer Center
Karolinska, Karolinska University Hospital R8:04, Stockholm SE-171 76, Sweden
Full list of author information is available at the end of the article
© 2013 Hashemi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Hashemi et al. BMC Cancer 2013, 13:505 Page 2 of 13
http://www.biomedcentral.com/1471-2407/13/505Background
Small intestinal neuroendocrine tumor (SI-NET) arising
from enterochromaffin cells is the most common type of
gastrointestinal endocrine tumor. SI-NET is also termed
midgut carcinoids, well-differentiated neuroendocrine tumor
of the midgut, ileal carcinoid or neuroendocrine tumor of
the midgut [1,2]. The tumors are usually slow-growing in
nature [3,4]. SI-NETs are mostly sporadic, however, a few
small families with a history of the disease have recently
been characterized [5,6]. Many patients are asymptomatic
and the disease can be indolent for many years and diag-
nosed incidentally. Approximately 20% of patients present
with carcinoid syndrome, a clinical entity characterized by
flushing, diarrhea, abdominal pain, cardiac valvular fibrosis
and bronchial constriction [7,8]. The clinical picture of the
carcinoid syndrome, which usually occur in patients with
liver metastases, is due to excessive production and release
of hormones and substances such as serotonin, tachykinins
and prostaglandins [9]. Metastases are first recognized in re-
gional lymph nodes followed by the liver and less frequently
in the ovaries or other distant sites [3,10]. Surgery is the first
treatment of choice, however, in patients with metastatic
disease surgical treatment seldom leads to cure [11].
Several molecular cytogenetic studies have been per-
formed with the aim of understanding the mechanisms
of SI-NET development. Using conventional compara-
tive genomic hybridization (CGH) we and others observed
frequent copy number (CN) losses at 18q, 11q, 16q, and
gains of 4p [12,13]. The most common aberration, loss of
18, was also identified by loss of heterozygosity (LOH)
screening [14] and has been validated in SI-NET by sev-
eral other groups using array CGH (a-CGH) or single
nucleotide polymorphism based arrays (SNP-arrays)
[5,15-17]. These findings suggest the location of putative
tumor suppressor gene(s) for SI-NET development in
chromosome 18. In addition, the possibility of two or
more genetically distinct groups in SI-NET has been sug-
gested, namely those characterized by loss of chromosome
18 and a second group with gain of chromosomes 4, 5, 7
and 14 [15,16]. SI-NETs with gain of chromosome 14 were
reported to have intact chromosome 18 and poor progno-
sis [15]. However, so far no target gene or genes have been
identified for the frequent genetic aberrations in SI-NETs.
To further refine and define regions of recurrent CN aber-
rations (CNAs) we applied a-CGH and genomic quantitative
real-time PCR (qPCR) to a panel of SI-NETs from 32 pa-
tients and evaluated the findings to the clinical parameters
and patient outcome. We also aimed to identify differences
in CNA profiles between primary tumors and metastases.
Methods
Tumor material
Fresh frozen samples from patients with sporadic SI-NETs
were included in this study. All tumor samples wereobtained from patients operated for SI-NETs at the
Karolinska University Hospital-Solna since 1989 and had
been collected and stored at the Karolinska tissue biobank.
All samples were obtained with informed oral consent
and ethical approval from the local ethical committee of
Karolinska Institutet. A standardized procedure of tumor
collection was employed including macroscopical dissec-
tion by a histopathologist, snap freezing and storage at
−80°C until use. The histopathological diagnosis was estab-
lished at routine examination according to published criteria
[9,18]. The immunohistochemical examination included
staining for chromogranin A [19], and/or Grimelius silver
staining and Masson staining as a marker for serotonin [12].
Totally 30 tumor samples (19 primary tumors and 11
metastases) from 29 patients (15 females and 14 males)
were collected for the a-CGH screening. For the subse-
quent qPCR analyses of selected loci the tumor sample
panel was extended to a total of 43 tumor samples from
32 patients. The clinical data concerning gender, age at
diagnosis of the primary tumor, functioning tumor, pre-
vious SI-NET surgery, metastasis and follow-up are de-
tailed in Additional file 1: Table S1. Eighteen tumors
from 18 patients were from our previous publication
(cases 1–18, Table 1) [12]. Twenty-four of the samples
were primary tumors and 19 were metastases. Twelve of
the metastases were regional (mesenterial, regional
lymph nodes or omental) and 7 were distant metastases
(5 liver and two ovarian). Matched primary and meta-
static lesions were available from 9 out of 32 cases, and
for two cases two metastatic samples were included. A
sample of non-neoplastic tissue close to the primary
tumor from a SI-NET case was included as normal con-
trol for quantitative real time PCR (qTR-PCR). Sixteen
cases were female and 16 were male. The median age at
the time of surgery was 67.5 years (mean 65 years; range
39–80 years). Patients were followed-up from diagnosis
until death or last date of contact for a median of 88
months (mean 94 months; range 7–222). Seventeen pa-
tients were known to have a functioning tumor based on
carcinoid syndrome and/or increased levels of 5-HIAA.
Seven patients had been treated surgically before the op-
eration at which the sample studied was collected. In
addition, cases 1–8 were operated before the introduc-
tion of somatostatin analogues, which was subsequently
the standard peroperative treatment concerning cases
9–32. MIB-1 proliferation index was available for cases
19–32 which all showed <2% except in case 25 that
showed 2.5%. In cases 1–18 the primary tumor was oper-
ated in the period 1986–1997 i.e. before the introduction
of MIB-1 analysis in the clinical workup of these tumors.
DNA extraction
Genomic DNA was either available from our published
series of SI-NETs [12] or was isolated from frozen tissue
Table 1 Recurrent copy number losses detected by a-CGH in SI-NETs
Case no. P /
/ M Chr 9 Chr 11 Chr 13 Chr 16 Chr 18
1 M - 11q14.1-ter - 16q12.1-ter -
3 P 9 - 13q11-ter - 18
4 p - - - - 18
5 M - - - - 18
6 M - - - 16q12.2-ter 18
7 P - 11q14.1-ter 13q33.1 - 18p11.31; q12.1-ter
8 P - - - - -
9 M - 11q21-ter - 16q12.1-ter 18
10 P - - - 18
11 P 9pter-13.2 11q13.4; q14.1-ter - - 18pter-q21.31
12 P - - - - 18
13 P - (11q23.1q-ter) - - (18)pter-11.23
14 P - - - -
15 P - - - - 18
16 P - - - - 18q22.1
17 P - - - - (18pter-11.21; q11.2-23)
18 P (9p13.1-q13.2) - 13q14.11-21.32 - -
20 P - - - - -
21 M - (11q13.3-ter) q13.3-13.5; q23.3-ter - 16p11.2; p11.2-11.1; q12.1-ter (18)pter-q11.2; q12.3-ter
23 M - - - - -
24 M 9 - 13 - 18
25 P - - - - -
26 P - - - 16p11.2 18
27 P - 11q22.1-ter - 16q12.1-ter 18pter-11.21
27 M - - - - -
28 M - - - - (18)18pter-11.23; q11.1-22.4
29 P - - - - -
30 M - - - - 18
31 P (9p13.1-q12) - - - 18p11.31
32 M 9p13.1-11.2 - - - 18
P = primary tumor; M = metastasis; chr= chromosome; Alterations written within parenthesis represent borderline alterations at the threshold.
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(Qiagen GmbH, Hilden, Germany) according to the
manufacturer’s protocol. The DNA quality and con-
centration was assessed using a NanoDrop A100 Spec-
trophotometer (ND-1000, Thermo Scientific, USA).
Array CGH (a-CGH) and data analysis
A-CGH was applied on 30 SI-NETs from 29 patients
using human BAC (Bacterial Artificial Chromosome) ar-
rays with 1 Mb resolution for 6 samples (cases 1, 3, 4, 6,
7, and 9), or of tiling type for 27 samples from 26 cases
(1, 2, 4, 5, 6, 8, 10–32). Initially, we used commercially
available 1 Mb arrays (Spectral Genomics, Houston, TX
USA currently Perkin Elmer) applying previously describedmethodology [20]. Briefly, a dye swap method was applied,
and the Spectralware 2 software (Spectral Genomics) was
used for data analysis with cut-off levels at 1.2 and 0.8 for
identification of gain or loss, respectively. Subsequently,
human tiling 33 K and 38 K BAC arrays, produced at the
SCIBLU Genomics Centre at Lund University, Sweden
(www.lu.se/sciblu) were used. The 33 K and 38 K array
slides contained 33,370 and 38,000 BAC clones, respect-
ively (CHORI BACPAC resources) (http://bacpac.chori.
org/ genomicRearrays.php) giving a resolution of one clone
per 50–100 kb. Information about experimental proce-
dures and data analyses have previously been described in
detail [21]. After hybridization, slides were scanned using a
Genepix 4200A scanner (Axon instruments Inc., Union
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the GenePix Pro 6.0 package analysis software (Axon in-
struments, Wheatherford TX, USA) and gene pix result
(GPR) files were generated. The GPR files were then loaded
onto BioArray Software Environment (BASE; http://base.
thep.lu.se/) [22] for further analyses and data processing
such as filtering, normalization, smoothing and profiling.
Log2 ratio thresholds were used to define gain (+0.25),
loss (−0.25), amplification (+1) and homozygous loss
(−1). Software based profiles were inspected manually
for confirmation of CNAs. Recurrent regions of CNAs
were defined as those observed in three or more a-CGH
profiles [23]. Inside recurrent regions, minimal overlap-
ping regions (MOR) were identified as the smallest region
of overlapping loss or gain. CNA regions in telomeric and
centromeric regions as well as involving few clones only
were interpreted with caution. CNAs overlapping with
known normal genomic variants according to the Data-
base of Genomic Variants (http://dgvbeta.tcag.ca/dgv/app/
home?ref=NCBI36/hg18) were not reported.
For cluster analysis of recurrent regions of CNAs, a
binary matrix was generated where the rows indicated
altered chromosomal regions and columns represented
the tumor samples. In each case copy number alterations
for each case CN status was coded as “0” for normal
copy number or “1” for CNA either gain or loss. The
matrix was uploaded in Multi Experiment Viewer 4.7.4
software and unsupervised hierarchical clustering analysis
was performed using Euclidean distance and average
linkage [24]. CNA data for case 27 with paired primary-
metastasis samples were pooled.
Genomic quantitative real-time PCR (qPCR)
qPCR analysis of CNs was applied to all 43 SI-NETs for
selected loci with frequent CN losses in 18p (EMILIN2),
18q (DCC, BCL2, CDH19), 16q (CDH1) and 11q (SDHD).
All target and reference assays were purchased from Ap-
plied Biosystems. RNaseP (on chromosome 14) was used
as endogenous control for normalization of analyzed loci
in chromosomes 18, 16 and 11. The following assays
were used: EMILIN2 (Hs01996822), DCC (Hs02317964,
Hs02967342), BCL2 (Hs01500302), CDH19 (Hs02826809,
Hs02956257), CDH1 Hs00934267), SDHD (Hs03794135)
and RNaseP (part number 4403326). Assays were chosen
to avoid overlap with known SNPs. The experimental pro-
cedure recommended by the manufacturer (Applied Bio-
systems) was followed. Five nanogram genomic DNA was
used in the qPCR reaction, and water was analyzed in par-
allel as negative control. All qPCR reactions were run in
quadruplicate in a Step One Plus qRT-PCR machine (Ap-
plied Biosystems) using standard cycling conditions of 10
min at 95°C, followed by 40 cycles of [95°C for 15 sec and
at 60°C for 1 min]. Pooled normal blood DNA (Promega,
Madison, WI, USA) was used as calibrator and a normalmucosal intestine DNA as normal control. CNs were pre-
dicted by Copy Caller v1.0 software (Applied Biosystems).
Statistical analysis
The follow-up period was calculated from the date of
diagnosis of the primary tumor until the date of death or
the last date of contact. The log rank test was used to
calculate overall survival and illustrated by Kaplan-Meier
plots concerning tumor groups, recurrent region of
CNAs and clinical parameters. Moreover to evaluate the
possible effect of confounding factors (e.g. gender or re-
gional, distant and extra-hepatic metastases) multivariate
analysis using Cox proportional hazards modeling was
applied to those recurrent regions of CNAs which were
significantly associated to survival. Associations be-
tween tumor groups and recurrent CNA or clinical pa-
rameters were evaluated by Fisher’s exact test and for
age at diagnosis by Mann–Whitney U test. All statis-
tical analyses were performed using the statistical Soft-
ware SPSS v 16.0. P-values ≤ 0.05 were regarded as
significant.
Results
Overall findings of copy number alterations detected by
a-CGH
We determined genome-wide CNAs in 30 tumors repre-
senting 19 primary tumors and 11 metastases from 29
patients with SI-NET using a-CGH. All samples ana-
lyzed displayed CNAs, with the largest and smallest ex-
tent of total CNAs observed in tumors number 4 (550
Mb) and 29 (2.5 Mb), respectively. CN losses and gains
were in many cases extensive and involved entire or al-
most entire chromosomes. Gains were more common
than losses. Recurrent CN losses were found on chro-
mosomes 18, 16, 11, 9 and 13 (Table 1) and gains on
chromosomes 20, 14, 4, 5, and 7 (Table 2). Overall the
CNAs detected by a-CGH in this study were consistent
with those detected for the 17 cases analyzed by meta-
phase CGH in our previous study [12] as well as with
those samples analyzed by the 1 Mb resolution array.
However, a-CGH identified additional CNAs not previ-
ously detected by metaphase CGH such as loss of 18p in
case 4, 10 and 15 or gains of chromosomes 4 and 5 in
case 14.
Copy number losses
Recurrent CN losses were most frequently found on
chromosomes 18 (70%), 11q (23%), 9 (20%), 16 (17%)
and 13 (13%). Fifteen of 30 tumors (50%) had entire or
almost entire loss of chromosome 18. In addition, loss of
chromosome 18 was the only detectable recurrent CNA
in four tumors (5, 10, 12, and 17), three of which were
primary tumors. Sub-chromosomal losses of chromo-
some 18 were observed in six tumors (Table 1, Figure 1).
Table 2 Recurrent copy number gains detected by a-CGH in SI-NETs
Case no. P /
/ M Chr 4 Chr 5 Chr 7 Chr 14 Chr 20
1 M (4)pter-15.32 (5)pter-15.33; q23.3-ter - (14q11.1-21.3);
q32.12-ter
20
3 P - - - - -
4 P (4)pter-15.2;
p14-qter
(5)pter-15.1; p13.3-qter - - (20)pter-q13.33
5 M - - - - -
6 M - - - - -
7 P 4 5 - 14 -
8 P - - - - -
9 M (4) - - - 20q12-ter
10 P - - - - -
11 P - - - - -
12 P - - - - -
13 P - - - - -
14 P (4)pter-16.1;
p14-q12
(5)pter-14.3; q35.1-ter - - (20)pter-13; q11.21-ter
15 P - - - - 20q13.32; qter
16 P - - - - 20q11.1-11.21; q13.33
17 P - - - - -
18 P - - - - -
20 P - - - 14q11.2 -
21 M - - 7q22.3-ter - -
23 M - - - (14q11.2) -
24 M - - - - 20
25 P (4)p16.3-12;
q22.1-ter
(5)pter-q35.2 - (14) q11.1-32.2 -
26 P - - - - (20)pter-11.21; q11.23-13.33
27 P - - (7)pter-22.3; p15.3-q35;
q35-ter
(14) q11.2; q23.3-ter (20)pter-q13.2; q13.31-ter
27 M - - - (14q11.2) -
28 M 4pter-16.1 5pter; q35.2-35.3 7p22.3; p22.2-22.1; q22.1;
qter
14q11.2; q32.2-ter 20p12.1; q13.31-13.32;
q13.33-ter
29 P - - - - -
30 M - - - - -
31 P - - - - -




(14q11.1-32.31) q11.1 20pter-11.21; q11.23-ter
P = primary tumor; M = metastasis; chr= chromosome; Alterations written within parenthesis represent borderline alterations at the threshold.
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18p (pter-p11.21) and another on 18q (q12.1-q21.31)
(Figure 1). A MOR of loss of 247 kb was observed within
the 18pter-p11.21 interval at 18p11.32-p11.31 in tumor 31.
This MOR encompasses three known genes, KIAA0650,
LPIN2 and EMILIN2, and the loss of the latter was verified
by genomic qPCR. Another MOR of 2 Mb loss was identi-
fied in tumor 16 at 18q22.1 which encompasses the genesCDH7 and CDH19. However, we could not confirm the
loss of CDH19 on 18q22.1 in tumor 16 by qPCR.
Recurrent CN losses were observed on chromosome 16
in 5/30 (17%) tumors. A recurrent region of 34.5 Mb loss
which maps to 16q12.2-qter was detected in 5 tumors (1, 6,
9, 21, and 27P) (Figure 2A and Additional file 2: Figure S1).
This region encompasses tumor suppressor genes including
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Figure 1 Mapping of CN losses detected in chromosome 18 by a-CGH analysis. At the top, the location of the EMILIN2, DCC, BCL2, CDH19
genes analyzed by qPCR are indicated by arrows next to an ideogram of chromosome 18 (UCSC Genome Browser). Alterations in cases with
detected CN losses are schematically illustrated by bars with red indicating losses and green marking gains. Fifteen samples exhibited loss of the
entire chromosome 18, while samples 7, 11, 16, 17, 27P and 31 showed losses restricted to parts of the chromosome. Below are shown a-CGH
profiles for case 4 with entire chromosome 18 loss, case 27P with deletion of 18pter-11.21, and case 16 with a 2 Mb deletion at 18q22.1.
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Figure 2 Mapping of CN losses in (A) chromosomes 16 and (B) 11 (B) and (C) localization of CN gains in chromosome 14 by a-CGH. For
each chromosome is shown an ideogram (UCSC Genome Browser) together with bars indicating losses in green and gains in green. The
genomic location of the CDH1 and SDHD genes analyzed by qPCR are marked by arrows.
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(7/30). These tumors shared a recurrent region of 35.5 Mb
at 11q22.1-qter (Table 1; Figure 2B and Additional file 2:
Figure S1). This region encompasses several known tumor
suppressor genes with a role in apoptosis such as SDHD
and members of the cysteine-aspartic acid protease (caspase)
family including CASP4 and CASP12. Whole chromosome
9 loss was found in two tumors and segmental losses in four
tumors with recurrent regions at 9pter-p13.2 and 9p13.1-
11.2. Loss of entire chromosome 13 was found in one
metastasis and two primary tumors showed deletions
at 13q11-ter and 13q13-q21.32.
Copy number gains
Recurrent CN gains were found on chromosome 4 (27%),
5 (23%), 7 (13%), 14 (30%) and 20 (37%) (Table 2; Figure 2C
and Additional file 2: Figure S1). Several genes involved intumor development including a variety of growth factors
are located on these chromosomes. These include for ex-
ample FGF2, FGFB, FGFR3 on 4q; PDGFR, APC, TGFB1,
SMAD5 on 5; BRAF, IGFBP3, MDR1 on chromosome 7;
AKT1, BCL2L2, MAX, MMP14, DAD1 and DICER1 on 14,
and E2F1, CDH4, LAMA5,TNFRSF6B on chromosome 20.
A MOR of 230 kb gain at 14q11.2 downstream of the
DAD1 locus was observed in four tumors (20, 23, 27M,
28) which overlapped with partial or entire gains in five
other tumors (1, 7, 25, 27P, 32). This region encompassed
several genes among others DHRS4L2, REC8L1, IPO4,
PSME1 and PCK2. One tumor (case 25) displayed gain of
entire chromosome 14, and four tumors (1, 20, 23, 27M)
carried partial or small gain of 14 without harboring copy
number losses on chromosome 18. A MOR of 1.4 Mb
gain at the telomeric region of chromosome 20 (q13.33)
was detected in 9/30 cases (30%) (data not shown). The
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genes such as CDH4, LAMA5, RPS21, KIAA1510,
TNFRSF6B (M68, DcR3), RTEL, EEF1A2 and PTK6.
Verification of recurrent CNAs by qPCR
All CNAs identified by a-CGH were reviewed to identify
recurrent loss or gain regions. The selection of candidate
genes for validation were based on the most common
CNAs in the present study as well as candidate genes
identified from the literature [5,12,14-17,25] and their
potential role in tumorigenesis of SI-NETs. To validate
CNAs in the selected recurrent regions, qPCR-based
copy number analysis was used. For validation of CN
losses in chromosome 18, we selected EMILIN2 (p11.32-
31), DCC (q21.1-2), BCL2 (q21.33) and CDH19 (q22.1).
CNs in chromosome 18 were verified in 12/19 (63%) of
the tumors for EMILIN2, 11/18 (61%) for DCC, 11/17
(65%) for BCL2 and 11/18 (61%) for CDH19 (Additional
file 3: Table S2). Consistent results were obtained when
two different assays used for the same gene (DCC,
CDH19).
For losses on chromosomes 16 and 11, we selected









20 P 2/2 2/2
20 M (reg) -/2 -/2
21 M1 (ova) -/1 -/1
21 M2 (ova) 1/2 1/2
23 P -/2 -/2
23 M (reg) 2/2 2/2
24 M (reg) -/1 -/1
24 M (reg) 1/1 1/1
26 P 1/1 1/2
26 M (reg) -/2 -/2
27 P 1/2 2/2
27 M (reg) 2/2 2/3
28 P -/1 -/1
28 M (reg) 1/1 1/1
29 P 2/2 2/3
29 M (reg) -/2 -/2
30 P -/1 -/2
30 M (reg) 1/1 1/2
31 P 1/1 2/2
31 M (reg) -/1 -/2
32 P -/1 -/1
32 M (reg) 1/1 1/1
P = primary; M = metastasis; ova = ovarial; reg = regional 1 = loss; 2 = no abnorma
Chomosomal locations are according to the ensembl database (www.ensembl.org).verified respectively in 3/5 (60%) and 4/7 (57%) of tu-
mors with corresponding losses detected by a-CGH
(Additional file 3: Table S2). Taken together CNAs and
CNs detected by a-CGH were confirmed by qPCR in
61% and 78% of tumors respectively (Additional file 3:
Table S2).
In addition to the tumor panel screened by aCGH,
qPCR-based CN profiling was performed in additional
SI-NETs (Table 3). Overall, qPCR was carried out for 11
tumor pairs of which 9 were primary tumors with paired
metastases from the same patients and two were paired
metastases from the same individual (Table 3). CNAs for
the target genes detected by a-CGH and qPCR were
similar in primary tumors and corresponding metastases
in most patients, however, small differences were ob-
served at some loci.
Clustering analysis and associations to clinical parameters
for recurrent regions
The a-CGH data was subjected to hierarchical cluster ana-
lysis to detect tumor groups with similar patterns of
chromosomal alterations based on recurrent regions of CN
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Time 
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Figure 3 Unsupervised hierarchical clustering and overall survival for recurrent regions of CNAs in SI-NETs. (A) Clustering analyses
identified two tumor groups (I and II) as well as five chromosomal clusters (a-e). CNAs detected in the primary tumor and metastasis of case 27
were pooled to prevent magnification of alterations in multiple samples from the same case. (B) Kaplan-Meier plots showing shorter overall
survival for cases with gain in 20pter-p11.21. The table below indicates the number of subjects at risk at different time points during follow-up.
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http://www.biomedcentral.com/1471-2407/13/505chromosomal clusters -(a-e) were identified (Figure 3).
Tumor group I consisted of 23 tumors (7 metastases, 30%)
and group II contained 7 tumors (4 metastases, 56%).
Losses in chromosomes 18, 16 and 11 and gain of
chromosome 20 were found in both tumor groups.
Tumor group II was significantly enriched for all alterations
which were part of cluster-d including gains of chromo-
some 4 (P = 0.007), 5 (P = 0.003), 7p22.3 (P = 0.001),7p22.2-22.1 (P = 0.001), 7q22.1 (P = 0.001), 7q22.3-qter
(P = 0.006), 14q11.2 (P < 0.0005), and 14q32.2-32.31 (P <
0.0005). A significant correlation was also observed be-
tween group II and gain on 20pter-p11.21 (P = 0.014).
Cases with extra-hepatic metastases (10, 21, 25, 27 and
32; Additional file 1: Table S1), had a higher likelihood
to segregate into group II (P = 0.016) and harbored gains
on 7p22.3 (P = 0.018), 7p22.2-22.1 (P = 0.018), 7q22.1
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and 14q32.2-32.31 (P = 0.016). Loss on 16q12.2-qter was
more common in distant metastases compared with pri-
mary tumors (P = 0.003), and this loss along with gain on
7q22.3-qter were more common in metastases compared
to primary tumors (P = 0.016 and P = 0.047, respectively),
suggesting their involvement in tumor progression.
Next, we tested possible associations between CNAs in
recurrent regions and patient survival. CN gain in the
20pter-p11.21 region was associated with shorter overall
survival (P = 0.013) (Figure 3B). Cox proportional haz-
ards modeling supported this finding as no confounders
were found. No other significant associations were ob-
served between recurrent CNAs and survival. Losses on
9p and 18p as well as gain on 7q were associated with
younger age at diagnosis (P = 0.025-0.029). CN losses on
chromosomes 11 and 16 and gain on chromosome 20
were more frequent in female patients involving 11q23.1-
qter (P = 0.039), 16q12.2-qter (P = 0.019), 20pter-p11.21
(P = 0.017) and 20q11.1-11.21 (P = 0.039).Table 4 Comparison of CNAs by a-CGH in recurrent
regions in primary tumors and metastases
Recurrent region Detected in [number of cases / informative (%)]
Primary tumors Metastases All tumors
No of samples n = 18 n = 12 n = 30
Losses
9pter-p13.2 2 / 18 (11%) 1 / 12 (8%) 3 / 30 (10%)
9p13.1-11.2 3 / 18 (17%) 2 / 12 (17%) 5 / 30 17%)
11q23.1-qter 4 / 18 (22%) 3 / 12 (25%) 7 / 30 (23%)
13q14.11-21.32 2 / 18 (11%) 1 / 12 (8%) 3 / 30 (10%)
13q33.1 2 / 18 (11%) 1 / 12 (8%) 3 / 30 (10%)
16q12.2-qter 1 / 18 (6%) 4 / 12 (33%) 5 / 30 (17%)
18pter-11.21 12 / 18 (67%) 8 / 12 (67%) 20 / 30 (67%)
18q12.1-21.31 10 / 18 (56%) 8 / 12 (67%) 18 / 30 (60%)
Gains
4pter-qter 4 / 18 (22%) 4 / 12 (%) 8 / 30 (27%)
5pter-qter 4 / 18 (22%) 3 / 12 (25%) 7 / 30 (23%)
7p22.3 1 / 18 (6%) 2 / 12 (17%) 3 / 30 (10%)
7p22.2-22.1 1 / 18 (6%) 2 / 12 (17%) 3 / 30 (10%)
7q22.1 1 / 18 (6%) 2 / 12 (17%) 3 / 30 (10%)
7q22.3-qter 1 / 18 (6%) 3 / 12 (25%) 4 / 30 (13%)
14q11.2 4 / 18 (22%) 5 / 12 (42%) 9 / 30 (30%)
14q32.2-32.31 3 / 18 (17%) 3 / 12 (25%) 6 / 30 (20%)
20pter-p11.21 4 / 18 (22%) 4 / 12 (33%) 8 / 30 (27%)
20q11.1-11.21 5 / 18 (28%) 2 / 12 (17%) 7 / 30 (23%)
20q12-qter 6 / 18 (33%) 5 / 12 (42%) 11 / 30 (37%)Discussion
In this study we report frequent CN losses of chromo-
some 18 as well as of chromosomes 16q, 11q, 13 and 9
and gains of chromosomes 20, 14, 4, 5 and 7. These
findings are in line with another Swedish study using a
similar platform to identify CNAs in SI-NETs [15], and
using a parallel exome sequencing approach to find re-
gions of recurrent losses and gains and mutated candi-
date genes therein [26]. For some recurrent regions
CNAs were more frequently observed in metastases than
in primary tumors such as loss of 16q (33% vs. 6%) and
gain of 7q (25% vs. 6%) (Table 4). The observations of
more genetic aberrations in metastases compared to pri-
mary tumors indicate that genetic changes accumulate
during tumor progression.
Loss of chromosome 18 was the most prominent alter-
ation observed in 70% of all tumors. This result is in
agreement with previous studies and confirms the high
frequency of chromosome 18 loss in SI-NETs [12,14,15].
Loss of chromosome 18 was the only detectable recur-
rent CNA in four tumors of which three were primary,
suggesting a potential role in tumor initiation. We iden-
tified two recurrent regions of losses of 18p and 18q and
a 247 kb MOR of loss at the EMILIN2 locus within the
pter-11.21 interval which was verified by qRT-PCR.
EMILIN2, which is a component of extracellular matrix,
suppresses the growth of cancer cells and has a role in
cell survival and apoptosis [27]. In addition, methylation
of EMILIN2 is associated with poor outcome in breast
cancer [28]. Another MOR of 2 Mb loss was observed at
18q22.1 in one tumor which overlapped with losses in
17 other tumors. Losses involving18q22.1 have been re-
ported by several groups, and a 40 kb CN variation in
18q22.1 has been reported to be over-represented in SI-
NET patients [17]. Furthermore, this region corresponds
to one of the three MOR of deletions (R2) described
in familial SI-NET [5]. This region encompasses the
CDH19 and CDH7 genes, however, we could not con-
firm the loss of CDH19 in tumor 16 with the small de-
letion in 18q22.1. This could be due to mixed tumor
populations giving variable results for this particular
tumor or represent an artifact finding. Mutation analyses
of genes in the 18q22.1 region including CDH7 and
CDH19 did not reveal any tumor specific mutations [5],
suggesting that other mechanisms of gene inactivation are
operational.
Nine of the 30 tumors (30%) had intact chromosome
18 (Table 1). Three of these (20, 23, 27M) had only re-
current gains of chromosomes 14, two tumors (8, 29)
were intact even for other recurrent alterations and the
other tumors had gains of 14 together with other alter-
ations such as gains of chromosomes 4 and 5 or losses
involving chromosomes 3, 9, 11, 13 and 16. This finding
is in agreement with previous reports and supports the
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in SI-NETs [15,16]. However, a mutually excluding rela-
tionship between loss of 18 and gain of 14 observed in
another cohort [15], was not revealed in our study. Fur-
thermore we did not find an association between gain of
14 and poor survival, as reported in another cohort [15].
Four of 12 (33%) metastases had loss at 16q as com-
pared to 1/18 (6%) primary tumors confirming our pre-
vious observations by conventional CGH [12], and
suggesting a role in SI-NET progression. By contrast, an-
other study reported that losses on 16q are more fre-
quent in primary tumors than in metastases [15]. This
discrepancy could be due to the different type of metas-
tases used in different studies. A possible role of
chromosome 16 loss in tumor progression is supported
by studies of other tumor types, e.g. advanced prostate
cancer and relapses of Wilm’s tumor showing frequent
LOH in 16q [29]. Using qPCR we confirmed CNAs at
the CDH1 gene locus, located in the MOR of 561 kb at
16q22.1, in 60% of cases. CDH1 is inactivated by muta-
tion or promoter hypermethylation in e.g. gastric and
breast cancers [30,31]. Inactivation of CDH1 is associ-
ated with its dysfunction in cell-cell adhesion as well as
triggering of cancer invasion and metastasis. We have
also observed promoter hypermethylation of CDH1 in
SI-NETs (Fotouhi et al., unpublished data). Thus, CDH1
could represent a potential candidate tumor suppressor
gene in this region.
CN losses within 11q have been reported for many
cancer types and have been associated with metastatic
disease for example in pheochromocytoma [32]. Loss of
11q is also linked to a high risk of relapse in neuroblast-
oma and poor clinical outcome in oral cancer [33,34]. In
the present study, losses of 11q were frequently observed
at almost similar frequencies in primary tumors (22%)
and metastasis (25%).
In addition to gain of entire chromosome 20, a 1.4-4.2
Mb region at 20q13.33 was gained in about 33% of tu-
mors. Similar alterations have been reported in e.g. di-
gestive tract tumors and breast cancer [35,36], and have
been correlated with lymph node metastasis in gastric
cancer [37]. Furthermore, the 20q13 region has been re-
ported as the most commonly amplified region in cancer
and 13 of the amplified genes were proposed as “cancer
initiating genes” [38]. Several cancer-related genes are
located on 20q13. TNFRSF6B, that may inhibit apoptosis
and promote cell survival, is over-expressed in gastro-
intestinal tract tumors [39], colorectal carcinoma [40]
and gastric cancer [41]. Furthermore cases with gain of
20pter-p11.21 exhibited shorter overall survival, support-
ing a role of this alteration in aggressive SI-NET. How-
ever, since only 7 cases showed gain of this region, the
association is based on a limited number of cases and firm
conclusions would require analysis of additional cases.Unsupervised clustering of all CNAs identified two
distinct tumor groups (I and II) and 5 chromosomal
clusters (a-e). Interestingly, gains of chromosomes 4, 5, 7
and 14 clustered together in tumor group II. This dis-
tinct genetic alteration in SI-NETs is in accordance with
a previous study [16]. Four metastases including two dis-
tant metastases (21, 27) which harbored losses of 16q,
clustered together with loss of chromosome 11 (cluster-c).
We investigated if different tumor groups and chromo-
somal clusters are associated with clinical variables or
tumor types. As shown in Figure 3, clusters-d and b alter-
ations (gains of 4, 5, 14 and 20) in tumor group II com-
prised a higher number of metastases (57%) than group I
(32%). This finding suggests a possible role for gain of
chromosomes 4, 5, 14 and 20 in progression of primary
tumors to metastases in SI-NETs. In addition tumors with
gain of 20pter-p11.21 were also associated with tumor
group II (P = 0.014) and the patients had a shorter
overall survival (P = 0.013). Female patients more fre-
quently showed losses on chromosomes 11q and 16q
and gains on 20p and 20q. Furthermore, gain on 7q
and loss on chromosomes 9p and 18p were associated
with younger age at diagnosis.
Conclusions
We identified two recurrent regions on chromosome 18
with a possible role in tumor initiation. Recurrent CN
gains of chromosomes 4, 5, 7, 14 are usually concomitant
and could together with loss of 16q and gain of 20p be in-
volved in progression of SI-NETs. Distinct genetic alter-
ations and pathways are involved in SI-NET development.
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